文献速递产科妇科

高强度聚焦超声与子宫动脉栓塞治疗剖宫产瘢痕妊娠的疗效与安全性比较:一项Meta分析

Efficacy and Safety of High-intensity Focused Ultrasound Compared with Uterine Artery Embolization in Cesarean Section Pregnancy: A Meta-analysis.
PubMed 文献 · J Minim Invasive Gynecol · 2023-03-07

该系统评价与Meta分析检索截至2022年9月30日的多个数据库,比较高强度聚焦超声(HIFU)与子宫动脉栓塞(UAE)治疗剖宫产瘢痕妊娠(CSP)的疗效与安全性。HIFU组成功率更高(OR=1.90,95%CI 1.06-3.41,p=.03),住院费用更低,但月经恢复时间较长,β-HCG正常化时间、术中出血、不良事件及住院时间无显著差异。作者认为HIFU有效、安全且经济,但结论需谨慎解读,因存在显著异质性,尚需大样本严格设计的临床试验验证。

要点

  • HIFU组治疗成功率高于UAE组(OR=1.90,95%CI 1.06-3.41,p=.03,I²=0)。
  • UAE组月经恢复时间短于HIFU组(MD=2.72天,95%CI 1.32-4.12,p=.0001,I²=0)。
  • HIFU组住院费用低于UAE组(MD=-7488.49元,95%CI -8460.13至-6516.84,p<.000,I²=0)。

核心结论

  • HIFU治疗CSP具有满意的成功率,术中出血量、β-HCG正常化时间、不良事件及住院时间与UAE相似,但住院费用更低;作者认为HIFU是有效、安全且经济的治疗选择,但结论需谨慎解读,因存在显著异质性,尚需大样本严格设计的临床试验验证。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Cochrane、Scopus、Web of Science和Embase(截至2022年9月30日),由2名研究者独立审阅相关研究。
  • 纳入接受HIFU治疗的CSP患者,采用纽卡斯尔-渥太华量表和非随机研究方法学指数评价研究质量。
  • 共纳入6项研究比较UAE与HIFU的疗效与安全性;另汇总10项研究计算HIFU成功率,10项研究间无数据重叠。

主要发现

  • HIFU组成功率高于UAE组(OR=1.90,95%CI 1.06-3.41,p=.03,I²=0)。
  • HIFU组汇总成功率为0.94(95%CI 0.92-0.96,p=.04,I²=48%)。
  • 术中出血量(MD=-21.94 mL,95%CI -67.34至23.47,p=.34,I²=99%)和β-HCG正常化时间(MD=3.13天,95%CI 0.02-6.25,p=.05,I²=70%)两组无显著差异。
  • UAE组月经恢复时间短于HIFU组(MD=2.72天,95%CI 1.32-4.12,p=.0001,I²=0)。
  • 不良事件(OR=0.53,95%CI 0.22-1.29,p=.16,I²=81%)和住院时间(MD=-0.41天,95%CI -1.14至0.31,p=.26,I²=55%)两组无显著差异;HIFU组住院费用低于UAE组(MD=-7488.49元,95%CI -8460.13至-6516.84,p<.000,I²=0)。

关键数值与推荐

  • HIFU组成功率高于UAE组:OR=1.90(95%CI 1.06-3.41,p=.03,I²=0)。
  • HIFU组汇总成功率0.94(95%CI 0.92-0.96,p=.04,I²=48%)。
  • UAE组月经恢复时间较HIFU组短:MD=2.72天(95%CI 1.32-4.12,p=.0001,I²=0)。
  • HIFU组住院费用低于UAE组:MD=-7488.49元(95%CI -8460.13至-6516.84,p<.000,I²=0)。
  • 术中出血量MD=-21.94 mL(95%CI -67.34至23.47,p=.34,I²=99%),β-HCG正常化时间MD=3.13天(95%CI 0.02-6.25,p=.05,I²=70%),不良事件OR=0.53(95%CI 0.22-1.29,p=.16,I²=81%),住院时间MD=-0.41天(95%CI -1.14至0.31,p=.26,I²=55%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 结论应谨慎解读,因存在显著异质性。
  • 需大样本且严格设计的临床试验验证这些结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the efficacy and safety of high-intensity focused ultrasound (HIFU) compared with uterine artery embolization (UAE) in cesarean section pregnancy (CSP) and to calculate the success rate of HIFU. DATA SOURCES: We searched PubMed, Cochrane, Scopus, Web of Science, and Embase on September 30, 2022, and the related studies were independently reviewed by 2 researchers. METHODS OF STUDY SELECTION: Medical subject headings and relevant terms from other articles were used for the database search. Patients with CSP who underwent HIFU were included in this analysis. The following results were recorded: success rate, intraoperative blood loss, time for serum beta-human chorionic gonadotropin (beta-HCG) normalization and menstruation recovery, adverse events, hospitalization time, and hospitalization expenses. We used the Newcastle-Ottawa Scale scoring system and the methodological index for nonrandomized studies system to evaluate the quality of the studies. TABULATION, INTEGRATION, AND RESULTS: Data from 6 studies were used to compare the efficacy and safety of UAE and HIFU. We pooled the success rate of HIFU by including 10 studies. No data overlap between the 10 studies. Success rate was higher in the HIFU group (odds ratio [OR] = 1.90; 95% confidence interval [CI] 1.06-3.41; p = .03; I2 = 0). We performed the meta-analysis of single rate in R 4.2.0 software, and the success rate of HIFU group was 0.94 (95% CI 0.92-0.96; p = .04; I2 = 48%). Intraoperative blood loss (mean difference [MD]= -21.94 mL; 95% CI -67.34 to 23.47; p = .34; I2 = 99%) and time for serum beta-HCG normalization (MD = 3.13 days; 95% CI 0.02-6.25; p = .05; I2 = 70%) were not significantly different. Time to menstruation recovery (MD = 2.72 days; 95% CI 1.32-4.12; p = .0001; I2 = 0) in the UAE group was shorter than that in the HIFU group. Adverse events were not significantly different between the 2 groups (OR = 0.53; 95% CI 0.22-1.29; p = .16; I2 = 81%). Hospitalization time was not significantly different between the HIFU and UAE groups (MD = -0.41 days; 95% CI -1.14 to 0.31; p = .26; I2 = 55%). Hospitalization expenses of the HIFU group were lower than those of the UAE group (MD = -7488.49 yuan; 95% CI -8460.13 to -6516.84; p <.000; I2 = 0). Heterogeneity of the time for beta-HCG normalization, adverse events, and hospitalization time were improved after excluding one study, and HIFU showed better results in the sensitivity analysis of adverse events and hospitalization time. CONCLUSION: According to our analysis, HIFU demonstrated satisfactory treatment success, accompanied by similar intraoperative blood loss, slower normalization of beta-HCG levels, and menstruation recovery, but potentially shorter hospitalization time, lower adverse events and lower costs than UAE. Therefore, HIFU is an effective, safe, and economical treatment for patients with CSP. These conclusions should be interpreted with caution because of the significant heterogeneity. However, large and strictly designed clinical trials are required to verify these conclusions.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Liu Y, Wang L, Zhu X, et al. Efficacy and Safety of High-intensity Focused Ultrasound Compared with Uterine Artery Embolization in Cesarean Section Pregnancy: A Meta-analysis. J Minim Invasive Gynecol. 2023. PMID: 36893898. doi:10.1016/j.jmig.2023.02.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。